Evidence map›Paper›PMID 39048743›Full record

Observational studyEuropean journal of pediatrics2024

Methylprednisolone pulse and prednisolone for intensification of primary treatment in Kawasaki disease patients at high risk of treatment resistance: a multicenter prospective cohort study.

Masaru Miura, Koichi Miyata, Tetsuji Kaneko, Shogo Akahoshi, Yoshihiko Morikawa, Takahiro Matsushima, Hiroshi Sakakibara, Tohru Kobayashi, Takahiro Nakamura, Tsutomu Takahashi and 3 more

Abstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in European journal of pediatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Masaru MiuraDepartment of Cardiology, Tokyo Metropolitan Children's Medical Center, 2-8-29 Musashidai Fuchu, Tokyo, 183-8561, Japan. masaru10miura@gmail.com.
Koichi MiyataDepartment of Cardiology, Tokyo Metropolitan Children's Medical Center, 2-8-29 Musashidai Fuchu, Tokyo, 183-8561, Japan.
Tetsuji KanekoClinical Research Support Center, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Shogo AkahoshiClinical Research Support Center, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Yoshihiko MorikawaClinical Research Support Center, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Takahiro MatsushimaDepartment of General Pediatrics, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Hiroshi SakakibaraDepartment of General Pediatrics, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Tohru KobayashiDepartment of Data Science, Clinical Research Center, National Center for Child Health and Development, Tokyo, Japan.
Takahiro NakamuraDepartment of Pediatrics, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan.
Tsutomu TakahashiDepartment of Pediatrics, Saiseikai Utsunomiya Hospital, Tochigi, Japan.
Maki NakazawaDepartment of Pediatrics, National Hospital Organization Saitama National Hospital, Saitama, Japan.
Akimichi ShibataDepartment of Pediatrics, Japanese Red Cross Ashikaga Hospital, Tochigi, Japan.
Hiroyuki YamagishiDepartment of Pediatrics, Keio University School of Medicine, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this study is to determine whether adding intravenous methylprednisolone pulse (IVMP) to primary adjunctive prednisolone with intravenous immunoglobulin (IVIG) improves treatment resistance and coronary artery aneurysms (CAA) in patients with Kawasaki disease (KD) with a high risk of treatment resistance. This multicenter, prospective, observational study was conducted at 28 hospitals in Japan from October 2016 to June 2020. For patients predicted to be resistant to treatment based on a Kobayashi score ≥ 5 and total bilirubin ≥ 1.0 mg/dL, each hospital independently decided to add IVMP followed by prednisolone, prednisolone alone, or nothing to the primary IVIG therapy. In total, 2856 consecutive KD patients were enrolled; of these, 399 (14.0%) were predicted to be treatment resistant. Patients who were resistant to the primary treatment and required additional treatment comprised 59%, 20%, and 26% of the IVIG-alone group, IVIG-plus-prednisolone group, and IVIG-plus-IVMP group, respectively (P < .0001). The CAA incidence (Z score ≥ 2.5) at month 1 was similar among the treatment groups (6.7%, 4.8%, and 7.3%, respectively; P = .66). CAA occurred more frequently in patients who needed third- or later-line therapy.Conclusions: Primary adjunctive corticosteroid therapy improved the treatment response and suppressed inflammation. However, the study found no benefit of adding IVMP to prednisolone therapy. Patients receiving IVIG alone achieved coronary outcomes comparable to those of patients receiving primary adjunctive corticosteroid therapy although they were more likely to require additional rescue treatment. KD inflammation should be resolved no later than the third line of additional treatment to reduce the risk of CAA.Trial registration: University Hospital Medical Information Network Clinical Trials Registry in Japan ( https://www.umin.ac.jp/ctr/index.htm ) under code UMIN000024937.

Indexed as

GlucocorticoidsImmunoglobulins, IntravenousMethylprednisoloneMucocutaneous Lymph Node SyndromePrednisoloneChild, PreschoolCoronary AneurysmDrug ResistanceDrug Therapy, CombinationFemaleHumansImmunologic FactorsInfantJapanMaleProspective StudiesGlucocorticoidsImmunoglobulins, IntravenousImmunologic FactorsMethylprednisolonePrednisoloneCoronary artery aneurysmsCorticosteroidKawasaki diseaseTreatment resistance

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.